Nanologica AB

NICA

SE0005454873

Commodity Chemicals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
1.200 ^SEK	+0.42%		+12.68%	-34.07%

Jun. 13	Nanologica Board Recommends Not To Accept Cash Offer Made By Flerie Invest	RE
Jun. 13	Nanologica's board of directors advises against accepting Flerie's mandatory bid offer.	FW

Flerie's portfolio company Nanologica has received an important order from a new customer

Published on 04/24/2025 at 04:15, updated on 04/24/2025 at 04:16

Stockholm, 24 April, 2025. Flerie AB's (publ) portfolio company Nanologica has announced that the company has secured an order for its silica-based purification media NLAB Saga® from a new customer in China.

The order for NLAB Saga® amounts to USD 180,000 and is expected to be delivered in the second quarter. The customer is a large pharmaceutical manufacturer and the order is for the evaluation of NLAB Saga® at production scale for use in the production of GLP-1 analogs, a rapidly growing area globally for the treatment of type 2 diabetes and obesity.

"This is very good news for Nanologica and an important step into the rapidly growing and strategically important GLP-1 segment. We look forward to following the company's continued development in China." says Mark Quick, Partner at Flerie.

Read Nanologica's full press release here: nanologica-ab-receives-order-worth-usd-180-000-from-new-customer-in-china.pdf

Flerie's holding in Nanologica amounts to 43%.

For more information:
Mark Quick
Email: ir@flerie.com

Latest news about Nanologica AB

Nanologica Board Recommends Not To Accept Cash Offer Made By Flerie Invest	Jun. 13	RE
Nanologica's board of directors advises against accepting Flerie's mandatory bid offer.	Jun. 13	FW
Nanologica's board of directors advises against accepting Flerie's bid	Jun. 13	FW
Nanologica Gets Order Of Appx. SEK 1.3 Mln	Jun. 12	RE
Nanologica receives order worth approximately SEK 1.3 million from new customer in the US	Jun. 12	FW
Nanologica receives SEK 38,000 from the exercise of TO5 - the subscription price was above the market price (R)	May. 26	FW
Nanologica receives SEK 38,000 from the exercise of TO5 - the subscription price was below the market price	May. 26	FW
Stockholm Bullets - Active Biotech climbs on positive study results	May. 23	FW
Flerie makes mandatory bid for Nanologica – offers SEK 1 per share	May. 23	FW
Flerie Invest AB proposed to acquire remaining 56.74% stake in Nanologica AB (OM:NICA) for SEK 50.1 million.	May. 22	CI
Nanologica AB Announces Board Resignations	May. 22	CI
Flerie triggers mandatory bid for Nanologica after further share acquisition	Apr. 28	FW
Redeye lowers motivated value for Nanologica to SEK 3.0 (3.5)	Apr. 24	FW
Nanologica Receives an Important Order from New Customer	Apr. 24	CI
Nanologica Wins Silica-based Purification Media Order from Chinese Customer	Apr. 23	MT
Nanologica receives order from new customer in China	Apr. 23	FW
Nanologica Receives Order Worth $180,000 In China	Apr. 23	RE
Nanologica AB Receives Order Worth USD 180,000 from New Customer in China	Apr. 23	CI
Stockholm Stock Exchange - Nordea report beats expectations	Apr. 16	FW
Nanologica increases turnover and reduces loss	Apr. 16	FW
Nanologica Q1 Operating Loss SEK 9.2 Mln	Apr. 16	RE
Nanologica AB Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 16	CI
Nanologica will release the interim report tomorrow, Wednesday	Apr. 15	FW
Nanologica Extends Loan From Flerie Invest To July 2, 2027	Mar. 24	RE
Nanologica extends existing loan from Flerie Invest by two years	Mar. 24	FW

Chart Nanologica AB

Duration

Period

NICA: Dynamic Chart

Company Profile

Nanologica AB (publ) is a Sweden-based materials development company. The Company specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The Company's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The Company's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)âs drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.

Employees

Sector

Commodity Chemicals

Calendar

Jul. 10 - Q2 2025 Earnings Release

More about the company